REVIEW ARTICLE

ISSN: 2455-8095
doi: https://doi.org/10.21477/ijapsr.9.1.02

Pharmaceutical Applications of Cryogenic Grinding: Enhancing Drug Properties

Sanket Jagdishchandra Soni[1*], Ankitkumar Natvarlal Patel[2]

[1]Associate Director, Department of Project and Portfolio Management, Amneal Pharmaceuticals, New Jersey, USA.
[2]Director of Formulation, Department of Formulation R&D, Amneal Pharmaceuticals, New Jersey, USA.

ABSTRACT

Cryogenic grinding is a revolutionary approach in pharmaceutical processing that grinds compounds to small particles at very low temperatures utilizing cryogenic fluids like liquid nitrogen or carbon dioxide. This technique keeps thermolabile chemicals' structure and bioactivity intact by avoiding heat production. It produces particles that are finer and more homogenous, which improves the solubility, dissolving rate, and bioavailability of the medicine. The stability and therapeutic effectiveness of heat-sensitive active pharmaceutical ingredients (APIs) depend on cryogenic grinding during processing. The benefits, advantages, and effects of cryogenic grinding on medication stability as well as its practical applications are discussed in this paper. Research on ibuprofen, curcumin, antibiotics, and chemicals derived from plants has shown their efficacy. In addition to comparing cryogenic grinding to more traditional processes, the study delves into the difficulties of the process, including the high operating costs and the necessary equipment. Newly developed therapeutic formulations and targeted drug delivery systems are expected to rely heavily on cryogenic grinding, thanks to developments in equipment design, integration of nanotechnology, and ecologically friendly techniques.

Keywords: Cryogenic grinding, thermolabile compounds, bioavailability, drug stability, liquid nitrogen, particle size reduction.

1. INTRODUCTION

Cryogenic grinding is a state-of-the-art method for processing materials that uses cryogenic fluids, including carbon dioxide or liquid nitrogen, to reduce compounds to exceptionally small particles at very low temperatures. To make the material brittle and simpler to grind, these cryogenic agents may bring its temperature down to its glass transition point. The pharmaceutical industry relies on this method heavily since thermolabile chemicals must have their stability, potency, and bioavailability preserved for them to be effective in treatment.[1]

When subjected to the high temperatures generated by traditional grinding processes, thermolabile compounds may undergo degradation or lose some of their chemical characteristics. This problem is mitigated by cryogenic grinding, which preserves the chemical structure and bioactivity of active pharmaceutical ingredients (APIs) by limiting heat buildup during grinding. Pharmaceutical substances are additionally protected from oxidation and volatilization by the low temperatures reached during cryogenic grinding.[2,3]

Cryogenic grinding not only keeps APIs chemically intact, but it also makes particles that are finer, more uniform, and have greater surface area. Particles of a smaller size are better able to dissolve in water and have a higher rate of bioavailability, which means that the body absorbs the medicine more quickly. For this reason, cryogenic grinding is an important step in creating safer and more reliable pharmaceutical formulations.[4,5]

The purpose of this paper is to provide an in-depth study of cryogenic grinding as it pertains to the processing of pharmaceuticals. It delves into the process's mechanism, highlighting the functions of the freezing, grinding, and collecting phases. Cryogenic grinding is outlined below, along with its benefits, how it affects medication stability and bioavailability, and some instances of its use in processing different pharmaceutical substances. Additionally, the article highlights the advantages and disadvantages of cryogenic grinding by comparing it with traditional grinding processes. In addition to pharmaceuticals, the study delves into the wider realm of cryogenic grinding and its uses in nutraceuticals, herbal remedies, and cosmetics. Lastly, the study delves into upcoming research trends, including topics such as environmentally friendly cryogenic grinding methods, improvements in equipment design, and targeted medicine delivery using nanotechnology integration.

Corresponding author
Sanket Jagdishchandra Soni
Email : Sanket45.com@gmail.com

Received: 09-11-2023 **Accepted:** 27-12-2023 **Available Online:** 01-01-2024

1.1. Steps involved in the cryogenic milling process

The following are the steps involved in the process of cryogenic milling (Figure 1).

1.1.1. *Material preparation*

- Chemical and physical qualities play a crucial role in the selection process for pharmaceutical powders or raw materials.
- To maximize efficiency, materials might be pre-processed or cooled down to a lower temperature prior to milling.[6]

1.1.2. *Cooling with a cryogenic agent*

Because of their distinct physical characteristics and ability to effectively sustain low temperatures, carbon dioxide and liquid nitrogen are the cryogenic fluids most often employed in pharmaceutical grinding.[7–10]

- *Liquid Nitrogen*

Rapid and effective freezing is provided by liquid nitrogen, which has a boiling point of -196°C. This ensures that the material stays brittle throughout the grinding operation. Because of its low boiling point, it absorbs heat quickly, protecting the grinding operation from temperature shifts. Liquid nitrogen is perfect for pharmaceutical applications that prioritize safety and purity since it is non-flammable, non-toxic, and ecologically friendly.[5,11]

- *Carbon Dioxide*

Sublimation point of carbon dioxide is -78.5°C, making it another efficient cryogenic fluid for grinding. Appropriate for materials that do not need significant freezing, it does not attain temperatures as low as liquid nitrogen.



Figure 1: Steps involved in cryogenic milling of pharmaceutical products

A viable option for industrial-scale pharmaceutical manufacture is carbon dioxide due to its accessibility, affordability, and lack of environmental impact.[12]

The grinding procedure keeps the material brittle and prevents heat production that may destroy heat-sensitive compounds by precisely controlling the temperatures of both cryogenic agents.

1.1.3. *Freezing (cryopreservation)*

- In order to stabilize the components before grinding, the materials undergo a cryopreservation procedure, which involves maintaining them at very low temperatures.
- Because certain active pharmaceutical ingredients (APIs) could be unstable at ambient temperature, this process is very helpful for protecting their structure and integrity.[13,14]

1.1.4. *Cryogenic grinding*

- Mechanical forces (such as collision and friction) disintegrate the particles of the frozen materials when they are fed into a milling chamber.
- The materials become more brittle at low temperatures, which makes them break more readily and efficiently, resulting in smaller particles.
- Grinding equipment designed for use in cold environments, such as ball mills or jet mills, is usually used at this stage.[15,16]

1.1.5. *Size homogenization*

- After the grinding process is complete, the particle size distribution is examined to make sure it is uniform and falls within the specified range.
- For pharmaceutical formulations to have dose consistency, it is necessary to re-grind or process any particles that are excessively large.[17]

1.1.6. *Separation and collection of fine powder*

- Utilizing sieves, classifiers, or filtering systems, the coarse powder is isolated from other by-products and larger sized particles.
- The next step is to gather the medication's fine powder for use in future formulations or packaging.[18]

1.1.7. *Quality control (QC)*

- Thorough quality control tests are performed on the milled powder to guarantee that its shape, particle size, and other significant characteristics are up to standard.
- An additional inspection may involve validating the uniformity of the granules, sustaining the activity of APIs, and ensuring that there are no contaminants.

1.1.8. Packaging

- Following successful completion of quality control, the fine powder is carefully packed to maintain its purity and avoid any potential contamination.
- Pharmaceutical powders are packaged in containers that are either waterproof or airtight to ensure their stability while being transported and stored.[19]

By adhering to these protocols, the pharmaceutical powders may be cryogenic milled without compromising with their quality or integrity.

1.2. MECHANISM OF CRYOGENIC GRINDING

Three primary steps comprise the cryogenic grinding procedure (Figure 2):[20–24]

1.2.1. Cooling

To lower the material's temperature below its glass transition point, cryogenic fluids like liquid nitrogen or carbon dioxide are used for pre-cooling. The material becomes more brittle after cooling, which increases the possibility of breaking during grinding. Cryogenic fluids allow for quick freezing, which keeps the material brittle during grinding, which reduces energy consumption and makes particle size reduction more efficient.[25,26]

1.2.2. Grinding

Hammer mills, attrition mills, and impact mills are examples of the specialized grinding equipment that use mechanical forces to process the cooled material. The fragile substance is mechanically pushed and then broken into small pieces using these devices. Grinding in a low-temperature setting avoids producing heat, a typical challenge with traditional procedures that may cause heat-sensitive compounds to degrade. To achieve the target particle size while maintaining the bioactivity and chemical stability of medicinal substances, this step is essential.[27–29]



Figure 2: Mechanism of cryogenic milling

1.2.3. Collection

To keep the fine powder from being exposed to temperature changes or reabsorption of moisture, it is collected under controlled conditions after grinding. When collecting powder, it's important to keep the temperature and humidity low so that the particles stay uniform in size, have good flow characteristics, and remain stable. Preventing aggregation and preserving the pharmaceutical product's integrity need proper collection and storage.[30,31]

The elimination of heat production as a byproduct of grinding is a key benefit of cryogenic grinding. Heat generated by friction, vibrations, and equipment operation during conventional grinding procedures may damage heat-sensitive chemicals and diminish their bioactivity. Because of the potential for oxidation, volatilization, and thermal deterioration brought on by heat production, medicinal substances risk losing some of their therapeutic effectiveness and chemical stability.[32]

In order to avoid these negative effects and retain the material's integrity and potency, cryogenic grinding keeps the temperature very low throughout the procedure. Particles are finer and more uniform, and the compound's solubility, dissolving rates, and bioavailability are all improved since no heat is generated, which preserves the molecular structure. This is of utmost importance for molecules that may be degraded by heat, known as thermolabiles. Pharmaceuticals made at low temperatures maintain their quality, performance, and stability over their entire life cycles because oxidation and chemical reactions are less likely to change the material's properties.[33,34]

1.3. Advantages of cryogenic grinding in pharmaceuticals

the following are the advantages of cryogenic milling over traditional methods of milling (Figure 3).

- By halting the heat deterioration of thermolabile substances, cryogenic grinding maintains their chemical stability and molecular structure, protecting them from degradation. Because of the potential for heat to diminish an API's potency and therapeutic effectiveness during the grinding process, this is of the utmost importance.[35,36]
- Cryogenic grinding reduces particle size and increases surface area by breaking the material into smaller, more uniform particles by subjecting it to very low temperatures, which cause it to become brittle. Particle size reduction improves bioavailability and therapeutic efficacy by increasing the solubility and dissolving rate of poorly soluble pharmaceuticals.
- Improving the dissolving time, bioavailability, and medication solubility: Particles having a larger



Figure 3: Advantages of cryogenic milling over traditional methods

surface area and a smaller diameter dissolve more quickly in biological fluids, which increases the bioavailability and rate at which drugs are absorbed. This is especially helpful for medications in BCS Classes II and IV that are poorly soluble and have a low oral bioavailability.[37,38]

- Elimination of processing-related oxidation and degradation: Pharmaceutical substances are protected from oxidation and other chemical processes that might damage them by using cryogenic grinding, which uses very low temperatures. Because of this, the finished product has a longer shelf life and maintains its potency and stability over time.
- Pharmaceutical powders benefit from cryogenic grinding's enhanced flow characteristics and less agglomeration since the process creates particles with uniform surfaces and consistent size distribution. As a result, pharmaceutical formulations are less likely to stick together, and their mixing, homogeneity, and consistency are all improved.[39,40]
- Product quality and therapeutic efficacy are both improved by cryogenic grinding's ability to produce uniformly sized particles, which guarantee constant medication supply in dosage forms.
- Cryogenic grinding improves efficiency and production by reducing energy consumption and taking advantage of the brittle condition of materials.
- Keeping volatile substances at low temperatures preserves their integrity and bioactivity, preventing their loss.[41]
- Contamination Prevention: The low-temperature setting lessens the likelihood of microbiological contamination and chemical reactions that can lower product quality.[42]
- The versatility of cryogenic grinding makes it an ideal process for a broad variety of materials, including complex formulations, heat-sensitive medicinal compounds, and volatile substances.[41,43,44]

1.4. Impact of cryogenic milling on drug properties

Cryogenic milling has the potential to greatly alter the characteristics of many drugs. The drug's solubility and dissolution rate are both enhanced by the reduction of particle size, which increases the surface area. The result is increased bioavailability and improved absorption. Additionally, the procedure preserves the drug's integrity by enhancing chemical stability and reducing heat breakdown. Cryomilling also enhances powder flowability, which helps make pharmaceutical formulations more consistent. Modulating polymorphic forms and particle size optimizes the drug release profile, enabling individualized release rates. Because cryomilling changes the texture of certain medications, it masks their bitter taste. Lastly, the finished product's formulation and stability are enhanced by cryogenic milling, which guarantees excipient compatibility (Table 1). The comparison of cryogenic and conventional grinding is provided in Table 2.

Table 1: Impact of cryogenic milling on drug properties

Property	*Effect of Cryogenic Milling*	*Examples*
Particle Size	Sizes of particles ranging from microns to nanometers	Ibuprofen, Phenytoin
Drug Solubility	Amorphization and decrease of particle size enhance solubility.	Ibuprofen, Carbamazepine, Phenytoin
Chemical Stability	A decrease in the rate of thermosensitive drug breakdown	Phenytoin, Indomethacin
Dissolution Rate	Quicker solubility, leading to enhanced bioavailability	Ibuprofen, Indomethacin
Powder Flowability	Processes with improved flow characteristics	Ibuprofen, Aspirin
Drug Release Profile	Enhanced regulated or prolonged release with an improved release profile	Ibuprofen, Phenytoin
Taste-Masking	Enhanced flavor masking in formulations for children and the elderly	Ibuprofen
Compatibility with Excipients	Facilitated better drug-excipient compatibility	Phenytoin with PVP, Carbamazepine with citric acid

Table 2: Comparison of cryogenic and conventional grinding

Parameter	*Cryogenic Grinding*	*Conventional Grinding*
Heat Generation	Minimal (due to low temperatures)	Significant (due to friction and impact)
Particle Size	Smaller, more uniform particles	Larger, less uniform particles
Solubility and Bioavailability	Enhanced due to increased surface area	Limited due to larger particle size
Preservation of Chemical Integrity	Maintained (no thermal degradation)	Compromised (heat-induced degradation)
Processing of Heat-Sensitive Drugs	Ideal for thermolabile compounds	Not suitable for heat-sensitive drugs
Oxidation and Volatilization	Minimal due to low temperatures	Higher risk due to heat exposure
Energy Consumption	Lower (due to brittle state of materials)	Higher (due to mechanical forces)

Table 3: Applications of cryogenic milling in pharmaceutical industry

Application	*Drug Example*	*Outcome*	*Reference*
Enhancement of Bioavailability	Ibuprofen	Smaller particles, faster dissolving, and more bioavailable	45,46
Stabilization of Thermosensitive APIs	Phenytoin	No breakdown during amorphization and enhanced chemical stability	19
Prevention of Polymorphic Transformations	Furosemide	Decreased mechanical breakdown and undesired polymorphism changes	47
Preparation of Inhalable Drug Formulations	Ibuprofen	Particles sized below the submicron range, making them inhalable	48
Nanoparticle Engineering for Targeted Delivery	Ibuprofen	New possibilities for tailored medication delivery and faster dissolution	46
Improved Drug-Excipient Compatibility	Phenytoin with PVP	The development of a stable glass solution improves compatibility	19
Enhanced Taste-Masking	Ibuprofen	Enhanced palatability for formulations intended for use in children and the elderly	45
Optimization of Drug Layering	Phenytoin with PVP	Cohesive medication stacking in multi-particulate systems	45
Improved Powder Flow for Tableting	Ibuprofen	Reduced problems with compaction and improved powder flowability	45
Co-Amorphization for Enhanced Stability	Phenytoin with PVP	Prolonged stability and improved solubility achieved via co-amorphization	19

1.5. Advantages of cryogenic grinding over traditional methods

- Maintaining molecular stability and integrity
- Improvements in bioavailability, dissolving rate, and solubility
- Enhanced powder flow characteristics with less aggregation
- Protection against heat deterioration and oxidation

1.6. Applications of cryogenic milling in pharmaceuticals for enhanced bioavailability and stability

The term "cryo-milling" refers to a technique that uses liquid nitrogen or another cryogen to grind materials at very low temperatures. The pharmaceutical industry is rapidly embracing this method to optimize formulation procedures and increase different medication characteristics. Cryogenic milling has significant uses in the pharmaceutical industry, as shown below with accompanying case studies (Table 3).

1.7. Enhancement of bioavailability in poorly soluble drugs

Enhancing the bioavailability of medications with low water solubility ranks high among the most pressing issues in the field of pharmaceutical research. A significant number of potential novel drugs have poor solubility, which hinders their ability to dissolve and be absorbed in the intestines. Classes II (low solubility, high permeability) and IV (low solubility, low permeability) of the Biopharmaceutics Classification System (BCS) describe these medications, which makes their formulation more difficult.[49]

By drastically decreasing particle size to the nano or sub-micron range, cryogenic milling increases the surface area-to-volume ratio and thereby solves this problem. The medicine is absorbed more effectively because of the increased surface area, which allows for speedier breakdown. Cryogenic milling also has the ability to partially amorphize crystalline medicines, which increases their solubility even more.

1.7.1. Case studies

- *Phenytoin*

In order to enhance the dissolution rates of phenytoin, a drug that is inadequately water-soluble, ultra-cryo milling was used to generate submicron particles.

- *Furosemide*

Cryogenic milling was used to reduce the particle size of furosemide, which enhanced its solubility characteristics.

- *Ibuprofen*

To improve ibuprofen's solubility and bioavailability, its particle size was reduced to the submicron level via cryogenic ball milling.[50]

A lipid-lowering medication called fenofibrate has a limited bioavailability due to its poor water solubility. Cryogenically milled fenofibrate has a far better dissolving rate than its traditionally milled counterpart.

- *Nifedipine*

Improved medication absorption is a result of cryogenically milling nifedipine, a calcium channel blocker used to treat hypertension.

- *Curcumin*

This natural substance, which has antioxidant and anti-inflammatory effects, is not very soluble when it is unprocessed. The therapeutic effectiveness is enhanced by cryogenic grinding, which reduces particle size and prevents heat degradation, hence improving solubility and bioavailability.[51]

Antibiotics (e.g., Amoxicillin, Erythromycin): During traditional grinding, the effectiveness of heat-sensitive antibiotics may be diminished. Their bioactivity and chemical structure are preserved via cryogenic grinding, guaranteeing that they maintain their therapeutic efficacy.[52]

Plant-Based Compounds (e.g., Flavonoids, Alkaloids): Heat and oxidation may degrade several plant bioactive chemicals. Their medicinal properties and pharmacological effectiveness are preserved and enhanced by cryogenic grinding, which prevents their deterioration.[53,54]

Cryogenic milling improves patient compliance by lowering the dosage required to achieve therapeutic effect while simultaneously decreasing the likelihood of adverse effects by increasing the pace at which these medications dissolve.

1.8. Stabilization of thermosensitive active pharmaceutical ingredients (APIs)

Temperature changes may significantly impact the activity of many active pharmaceutical ingredients (APIs), including biologics, peptides, and certain small-molecule medications. Traditional milling methods expose materials to high temperatures, which may cause them to degrade, lose their effectiveness, and undergo undesired chemical reactions. A method that minimizes thermal deterioration is cryogenic milling, which enables the processing of drugs at very low temperatures.

This is especially helpful for substances that are sensitive to heat, such as antibiotics and protein-based treatments.

For example:

- It is well-known that high temperatures cause the degradation of **erythromycin**, a macrolide antibiotic. To avoid this kind of deterioration and keep the medicine stable throughout processing and storage, cryogenic milling is used.[55]
- By preventing denaturation and aggregation, cryogenic milling preserves the bioactivity of **insulin and peptide-based medications**, including glucagon-like peptide-1 (GLP-1) analogs used to treat diabetes.[48]
- **Hormonal Drugs (Progesterone, Testosterone)**: Heat causes the degradation of some medications. Their medicinal efficacy is preserved during cryogenic milling.[56]

Furthermore, traditional milling might cause heat deterioration of several excipients, including polymers used in controlled-release formulations. Their structural integrity is preserved by cryogenic milling, which improves their effectiveness in drug delivery systems.

1.9. Prevention of polymorphic transformations

An example of polymorphism in the pharmaceutical industry would be a medicine that exists in more than one crystalline form, each of which has its own unique set of characteristics regarding bioavailability, stability, and solubility. There are polymorphic forms that are more stable but less soluble, and there are other forms that are more soluble but easily degraded.[57,58]

Inducing undesired polymorphic transitions during high-energy milling at ambient temperatures is a common occurrence, and it may affect therapeutic effectiveness and make regulatory clearance more difficult. Cryogenic milling protects against this by keeping the crystalline structure intact while reducing particle size.[59]

For example:

- The complicated polymorphic behavior of the anticonvulsant **carbamazepine** is well-known in the treatment of epilepsy. For constant solubility and therapeutic efficacy, cryogenic milling is a useful tool for keeping the target polymorphism form.[60]
- Cryogenic milling has reduced the possibility of variability in medication performance by improving

stability and polymorphic retention of the antipsychotic medicine **risperidone.**[61]

- Indomethacin is an NSAID that may be found in both crystalline and amorphous forms. To improve solubility and avoid crystallization, cryogenic milling is used.[62]

Cryogenic milling reduces the possibility of batch-to-batch fluctuations in medication quality and improves regulatory compliance by maintaining the ideal polymorphic form.

1.10. Preparation of inhalable drug formulations

Treatments for respiratory disorders including asthma, COPD, and pulmonary hypertension are best administered via the pulmonary system. To ensure effective lung deposition, medication particles should not exceed 1-5 μm in aerodynamic diameter. Traditional milling methods often produce agglomeration and particles with disproportionately large or small sizes, making it difficult to achieve the desired particle size distribution.[63]

Cryogenic milling is ideal for inhalable medication formulations because it produces particles that are small, homogeneous, and free of aggregates.

For example:

- To provide the best possible lung deposition of salbutamol sulfate, a bronchodilator used in the treatment of asthma, the particle size must be carefully controlled. The drug particles are kept within the optimal aerodynamic range during cryogenic milling, which improves their potency.[64]
- Cryogenic milling was utilized to make budesonide, an inhaled corticosteroid, more consistent and enhance its dispersibility.[65]
- Particle size management is essential for the successful pulmonary delivery of tiotropium bromide, a long-acting bronchodilator for chronic obstructive pulmonary disease (COPD).[66]

Improved medication delivery to the lungs is achieved by cryogenic milling, which enhances the performance of dry powder inhalers (DPIs) and pressurized metered-dose inhalers (pMDIs) by improving particle size distribution and flow characteristics.

1.11. Nanoparticle engineering for targeted drug delivery

Recently, there has been a lot of discussion about therapeutic formulations based on nanotechnology, especially in the areas of targeted drug delivery and cancer. Cryogenic milling is an effective method for creating therapeutic nanoparticles that have improved permeability and retention properties. The regulated release, improved solubility, and better deposition of the medicine at the target region are all benefits of these nanoparticles.

For example:

- Cryogenic milling was used to effectively produce nanosized particles of **paclitaxel**, an anticancer medication that has low solubility. This improved solubility and bioavailability of the medicine.[67]
- Cryogenic milling improves the solubility and bioactivity of **curcumin**, an organic substance having anti-inflammatory and anticancer potential.[51]
- The antifungal medication itraconazole is only partially soluble in water; however, it may be nanosized via cryogenic milling, which increases its systemic absorption.[17]

Modern drug administration methods, such as liposomal and polymeric nanoparticle formulations, are made possible by cryogenic milling, which reduces drug particle size to the nanoscale, improving drug absorption.

1.12. Enhanced drug-excipient compatibility and formulation stability

Conventional milling may cause deterioration, phase separation, or decreased effectiveness in drug-excipient combinations due to adverse interactions. By keeping the processing environment steady, cryogenic milling reduces the impact of these interactions to a minimum.

For example:

- Low-temperature processing helps avoid lipid oxidation and degradation in lipid-based formulations like self-emulsifying drug delivery systems (SEDDS).[68]
- Cryogenic milling preserves the polymer matrix, which is beneficial for controlled-release formulations since it allows for predictable drug release kinetics.[69]
- Hydrophilic Matrix Systems: Cryogenic milling improves medication solubility rates by increasing the homogeneity of hydrophilic excipients.[18]

Cryogenic milling improves the overall efficacy of drug formulations by maintaining the stability of active pharmaceutical ingredients and excipients.

1.13. Enhanced taste-masking in pediatric and geriatric formulations

Drugs with a bitter or unpleasant taste may be difficult to formulate, and this is especially true for younger and older patients who may have trouble swallowing or tolerating medications with weak flavors. Reducing the size of the drug particles and enhancing their encapsulation within taste-masking excipients are two ways cryogenic milling improves taste-masking.

1.13.1. Case studies

- *Acetaminophen (Paracetamol)*

The strong taste of this commonly used painkiller may be improved using cryogenic milling by coating it better with sweeteners and flavoring ingredients.

- *Metronidazole*

Cryogenic milling makes it possible to effectively include this antibiotic—which has a severe bitter taste—into taste-masking formulations.[70]

- *Ibuprofen Suspensions*

To promote patient compliance, liquid solutions of cryogenically milled ibuprofen may be added with better flavor masking.[71–73]

Cryogenic milling is crucial in pediatric and geriatric medicine because it allows for the creation of formulations that are more patient-friendly.

1.14. Optimization of drug layering in multiparticulate systems

The homogeneous stacking of pharmaceuticals onto carrier particles is necessary for multiparticulate drug delivery systems including microspheres, granules, and pellets. Using typically milled medication particles, which might have uneven forms and variable size distribution, makes it tough to provide a uniform coating. For better drug adherence and distribution in multiparticulate systems, cryogenic milling may be used to create ultra-fine, evenly sized drug particles.

1.14.1. Case studies

- *Extended-Release Capsules*

Cryogenic milling improves release kinetics by ensuring a homogeneous coating of drugs onto inert carriers.[74]

- *Orally Disintegrating Pellets*

Cryogenic milling of small medication particles increases administration compliance because of the speed with which the drug dissolves in the mouth.[75]

- *Biphasic Drug Delivery*

Cryogenic milling allows for extremely precise control of particle size, which is useful for drugs containing both immediate-release and sustained-release components.[51]

Keeping the drug release profiles constant is of the utmost importance in controlled-release and modified-release formulations, where this use proves to be quite effective.

1.15. Improved flow properties for powder processing and tableting

The inability to fill capsules uniformly, irregular dosage, and tablet weight fluctuation are all indications of pharmaceutical powders with poor flow characteristics. Powder flowability is enhanced via cryogenic milling, which reduces cohesion and produces homogeneous, free-flowing particles.

1.15.1. Case studies

- *Amorphous APIs*

Although many pharmaceuticals have poor flowability in their amorphous forms, cryogenic grinding enhances their handling characteristics.[76]

- *Direct Compression Tablets*

Tablets made from cryogenically milled powders are stronger and more consistent because of their improved compaction behavior.[77]

- *Dry Powder Inhalers (DPIs)*

Cryogenic milling guarantees the best powder dispersion for inhalation, which is essential for DPIs that rely on consistent powder flow.[78]

Cryogenic milling improves powder flow characteristics, which increases production efficiency and guarantees pharmaceutical goods of superior quality.

1.16. Co-amorphization for enhanced drug stability and performance

One way to make amorphous drug formulations more stable is to combine them with another stabilizing component, such an excipient or another active pharmaceutical ingredient (API). This process is called co-amorphization. Cryogenic milling improves medication solubility and prevents recrystallization by facilitating the creation of stable co-amorphous systems.

1.16.1. Case studies

- *Indomethacin and Saccharin*

The co-amorphous system enhances solubility of indomethacin by stabilizing it in its amorphous state with saccharin.[79]

- *Carvedilol and Tartaric Acid*

One way to improve the solubility and stability of a co-amorphous formulation is to use cryogenic milling.[80]

- *Atorvastatin and Amino Acids*

Atorvastatin is stabilized in a co-amorphous form by amino acids, which improves its bioavailability and prevents its breakdown.[81,82]

To guarantee long-term stability and constant therapeutic efficacy, this method is especially helpful for medications that crystallize over time.

1.17. Applications beyond pharmaceuticals

- Some dietary supplements and nutraceuticals undergo cryogenic grinding as part of their process-

ing to increase their stability, bioavailability, and solubility. These products are designed to be more effective and consistent, leading to higher health advantages.

- This method successfully preserves the therapeutic characteristics of medicinal plants while extracting and processing their bioactive ingredients.
- Cryogenic grinding is a technique that enhances the performance and quality of personal care products by creating fine powders with consistent particle size and a smooth texture. Additionally, heat-sensitive compounds maintain their bioactivity and stability throughout the process.

1.18. CHALLENGES AND LIMITATIONS OF CRYOGENIC GRINDING

- Cryogenic grinding is more costly than traditional procedures due to its high operating expenses and the specialized equipment and cryogenic fluids that are required.
- Safe Practices for the Handling of Cryogenic Gases: Strict safety standards must be followed while working with liquid carbon dioxide and nitrogen in order to avoid mishaps and guarantee the safe handling of cryogenic gases.
- The Need for of Specialized Spaces and Skilled Workers: The complexity and expense of cryogenic grinding are increased by the need for dedicated facilities and skilled workers to run and maintain the machinery.

1.19. FUTURE PERSPECTIVES AND RESEARCH TRENDS

- Continuous efforts are being made to enhance the effectiveness, accuracy, and extensibility of cryogenic grinding systems via research and technical developments. Reducing energy usage, improving particle size control, and increasing throughput are the goals of innovations in equipment design and process optimization.
- Improving solubility, bioavailability, and targeted medication administration are all possible outcomes of combining cryogenic grinding with nanotechnology to create nanoparticles. This paves the way for fresh opportunities in creating complex medication formulations with enhanced therapeutic effects.
- The use of less costly, more widely accessible, and ecologically friendly alternative coolants in cryogenic grinding operations is a topic of active research. These advancements are made to make cryogenic grinding more accessible and affordable for pharmaceutical production by lowering its operating expenses and environmental impact.

2. CONCLUSION

In order to improve the therapeutic effectiveness, bioavailability, and stability of heat-sensitive medications, cryogenic grinding is an impressive approach. Cryogenic grinding is an approach that preserves the chemical integrity of pharmaceutical compounds while limiting heat generation. It allows for the production of smaller, more uniform particles with increased solubility and dissolving rates, beyond the constraints of traditional grinding procedures. This procedure is crucial for processing volatile and thermolabile chemicals because it maintains their bioactivity and stability throughout production. Modern pharmaceutical processing relies on cryogenic grinding, despite the fact that it is more expensive to operate and necessitate sophisticated facilities and equipment. However, the advantages of cryogenic grinding, such as improved medication performance and therapeutic results, more than justify the investment. As technology continues to improve and methods become more eco-friendly, cryogenic grinding will be used more and more in the creation of new drug formulations and targeted drug delivery systems. This will lead to treatments that are both more effective and easier to access in the future.

3. REFERENCES

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
2. Chaumeil J. Micronization: a method of improving the bioavailability of poorly soluble drugs. Methods Find Exp Clin Pharmacol. 1998;20(3):211-215.
3. Soyata A, Kenti K, Sutoro M, Sagita ND. Impact of preparation method in co-amorphous system. Sci Pharm. 2022;1(1):34-40.
4. Sheth AR, Bates S, Muller FX, Grant DJ. Polymorphism in piroxicam. Cryst Growth Des. 2004;4(6):1091-1098.
5. Niu Q, Jing L, Yu Z, Li C, Qiu X, Ko T. Experimental study on cryogenic milling performance of SiCp/Al composites with liquid nitrogen. Mach Sci Technol. 2022;26(1):1-17.
6. Purvis T, Vaughn JM, Rogers TL, Chen X, Overhoff KA, Sinswat P, Hu J, McConville JT, Johnston KP, Williams III RO. Cryogenic liquids, nanoparticles, and microencapsulation. Int J Pharm. 2006;324(1):43-50.
7. Desprez S, Descamps M. Transformations of glassy indomethacin induced by ball-milling. J Non-Cryst Solids. 2006;352(42-49):4480-4485.
8. Willart JF, Caron V, Lefort R, Danede F, Prevost D, Descamps M. Athermal character of the solid state amorphization of lactose induced by ball milling. Solid State Commun.

2004;132(10):693-696.

9. Descamps M, Willart J, Dudognon E, Caron V. Transformation of pharmaceutical compounds upon milling and comilling: the role of Tg. J Pharm Sci. 2007;96(5):1398-1407.
10. Fukuoka E, Makita M, Yamamura S. Some physicochemical properties of glassy indomethacin. Chem Pharm Bull. 1986;34(10):4314-4321.
11. Kozlík J, Stráský J, Harcuba P, Ibragimov I, Chráska T, Janeček M. Cryogenic milling of titanium powder. Metals. 2018;8(1):31.
12. Sahakijpijarn S, Moon C, Williams III RO. Pharmaceutical cryogenic technologies. In: Formul Poorly Water Soluble Drugs. Springer; 2022:453-528.
13. Surasarang SH, Williams III RO. Pharmaceutical cryogenic technologies. In: Formul Poorly Water Soluble Drugs. Springer; 2016:527-607.
14. Phillips EO, Giovinazzi S, Menz SL, Son Y, Gunjan A. Preparation of cell extracts by cryogrinding in an automated freezer mill. J Vis Exp. 2021;167:1-15.
15. Li S, Ge S, Huang Z, Wang Q, Zhao H, Pan H. Cryogenic grinding technology for traditional Chinese herbal medicine. Cryogenics. 1991;31(2):136-137.
16. Saxena S, Barnwal P, Balasubramanian S, Yadav D, Lal G, Singh K. Cryogenic grinding for better aroma retention and improved quality of Indian spices and herbs: A review. J Food Process Eng. 2018;41(6):e12826.
17. Moribe K, Ueda K, Limwikrant W, Higashi K, Yamamoto K. Nano-sized crystalline drug production by milling technology. Curr Pharm Des. 2013;19(35):6246-6258.
18. Loh ZH, Samanta AK, Heng PWS. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian J Pharm Sci. 2015;10(4):255-274.
19. Sugimoto S, Niwa T, Nakanishi Y, Danjo K. Development of a novel ultra cryo-milling technique for a poorly water-soluble drug using dry ice beads and liquid nitrogen. Int J Pharm. 2012;426(1-2):162-169.
20. Chieng N, Zujovic Z, Bowmaker G, Rades T, Saville D. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1. Int J Pharm. 2006;327(1-2):36-44.
21. 21. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci. 2010;99(3):1254-1264.
22. Yoshioka M, Hancock BC, Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci. 1994;83(12):1700-1705.
23. Shamblin SL, Hancock BC, Pikal MJ. Coupling between chemical reactivity and structural relaxation in pharmaceutical glasses. Pharm Res. 2006;23:2254-2268.
24. 24. Di L, Loeff P, Bakker H. Atomic disorder in Nb3Sn during heavy mechanical impact. J Less Common Met. 1991;168(2):183-193.
25. Niwa T, Nakanishi Y, Danjo K. One-step preparation of pharmaceutical nanocrystals using ultra cryo-milling technique in liquid nitrogen. Eur J Pharm Sci. 2010;41(1):78-85.
26. Paul S, Chattopadhyay A. A study of effects of cryo-cooling in grinding. Int J Mach Tools Manuf. 1995;35(1):109-117.
27. Mirza R, Ahirrao S, Kshirsagar S. A nanocrystal technology: to enhance solubility of poorly water soluble drugs. J Appl Pharm Res. 2017;5(1):01-13.
28. Junghare H, Hamjade M, Patil C, Girase S, Lele M. A review on cryogenic grinding. Int J Curr Eng Technol. 2017;7(7):420-423.
29. Paul S, Chattopadhyay A. The effect of cryogenic cooling on grinding forces. Int J Mach Tools Manuf. 1996;36(1):63-72.
30. Ribeiro A, Montes F, Sousa J, Pais A. Comminution technologies in the pharmaceutical industry: a comprehensive review with recent advances. Rev Chem Eng. 2025;41(1):69-100.
31. Seibert KD, Collins PC, Luciani CV, Fisher ES. Milling operations in the pharmaceutical industry. Chem Eng Pharm Ind: Act Pharm Ingredients. Published online 2019:861-879.
32. Kishore K, Sinha MK, Singh A, Archana, Gupta MK, Korkmaz ME. A comprehensive review on the grinding process: advancements, applications and challenges. Proc Inst Mech Eng, Part C: J Mech Eng Sci. 2022;236(22):10923-10952.
33. Crowley KJ, Zografi G. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci. 2002;91(2):492-507.
34. Lam NQ, Okamoto PR, Li M. Disorder-induced amorphization. J Nucl Mater. 1997;251:89-97.
35. Zanolla D, Perissutti B, Passerini N, Invernizzi S, Voinovich D, Bertoni S, Melegari C, Millotti G, Albertini B. Milling and comilling Praziquantel at cryogenic and room temperatures: Assessment of the process-induced effects on drug properties. J Pharm Biomed Anal. 2018;153:82-89.
36. Gan Y, Wang Y, Liu K, Han L, Luo Q, Liu H. A novel and effective method for cryogenic milling of polytetrafluoroethylene. Int J Adv Manuf Technol. 2021;112:969-976.
37. Barnwal P, Mohite A, Singh K, Kumar P, Zachariah TJ, Saxena S. Effect of cryogenic and ambient grinding on grinding characteristics of cinnamon and turmeric. Int J Seed Spices. 2014;4(2):26-31.
38. Kaur B, Srivastav P. Effect of cryogenic grinding on chemical and morphological characteristics of mango (Mangifera indica L.) peel powder. J Food Process Preserv. 2018;42(4):e13583.
39. Saxena V, Patel BB, Sutar R, Joshi D. Improving quality of cumin powder through cryogenic grinding technology. J Food Process Preserv. 2018;42(1):e13371.
40. Sharma L, Agarwal D, Rathore S, Malhotra S, Saxena S. Effect of cryogenic grinding on volatile and fatty oil constituents of cumin (Cuminum cyminum L.) genotypes. J Food Sci Technol. 2016;53:2827-2834.
41. Sharma L, Agarwal D, Sharma Y, Rathore S, Saxena S. Cryogenic grinding technology enhances volatile oil, oleoresin and antioxidant activity of cumin (Cuminum cyminum L.). Int J Seed Spices. 2014;4(2):68-72.
42. Singh SS, Ghodki BM, Goswami T. Effect of grinding methods on powder quality of king chilli. *J Food Meas Charact*. 2018;12:1686-1694.
43. Descamps M, Willart J, Aumelas A. The glass transition of driven molecular materials. In: Vol 982. Am Inst Phys; 2008:53-61.
44. Fecht H. Defect-induced melting and solid-state amorphization. Nature. 1992;356(6365):133-135.
45. Chaudhary A, Nagaich U, Gulati N, Sharma V, Khosa R, Partapur M. Enhancement of solubilization and bioavailability

of poorly soluble drugs by physical and chemical modifications: A recent review. J Adv Pharm Educ Res. 2012;2(1):32-67.

46. Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines. 2022;10(9):2055.
47. Adrjanowicz K, Kaminski K, Grzybowska K, Hawelek L, Paluch M, Gruszka I, Zakowiecki D, Sawicki W, Lepek P, Kamysz W, Guzik L. Effect of cryogrinding on chemical stability of the sparingly water-soluble drug furosemide. Pharm Res. 2011;28:3220-3236.
48. Chougule MB, Padhi BK, Jinturkar KA, Misra A. Development of dry powder inhalers. Recent Pat Drug Deliv Formul. 2007;1(1):11-21.
49. Shah P, Goodyear B, Michniak-Kohn BB. A review: Enhancement of solubility and oral bioavailability of poorly soluble drugs. Adv Pharm J. 2017;2(5):161-173.
50. Rhee KY, Cho HK, Hong JS. An investigation on the application of cryogenic ball milling to ibuprofen particle and its characteristics. In: Mater Sci Forum. Vol 505. Trans Tech Publ; 2006:355-360. Accessed March 7, 2025. https://www.scientific.net/MSF.505-507.355
51. Chen G, Liu Y, Svirskis D, Li H, Ying M, Lu W, Wen J. Cryo-Milled β-Glucan Nanoparticles for Oral Drug Delivery. Pharmaceutics. 2024;16(4):546.
52. Lolo M, Pedreira S, Vázquez BI, Franco CM, Cepeda A, Fente CA. Cryogenic grinding pre-treatment improves extraction efficiency of fluoroquinolones for HPLC-MS/MS determination in animal tissue. Anal Bioanal Chem. 2007;387:1933-1937.
53. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17:397-404.
54. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals–special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011;78(1):1-9.
55. Ershaid JMA, Abudoleh SM, Lafi DN. Freeze-dried erythromycin nanocrystals: preparation, characterisation, antimicrobial activity, and aerodynamic properties. Pharmacia. 2024;71:1-10.
56. Osetsky A, Grischenko V, Goltsev A, Kravchenko M, Stryuchkova E. Cryogenic technologies in production of pharmaceutical, cosmetic, agrotechnical formulations and biologically active food additives. Probl Cryobiol Cryomed. 2009;19(4):488-499.
57. Sood J, Sapra B, Bhandari S, Jindal M, Tiwary AK. Understanding pharmaceutical polymorphic transformations I: Influence of process variables and storage conditions. Ther Deliv. 2014;5(10):1123-1142.
58. Feng Y, Wang H, Wu D, Chen K, Wang N, Wang T, Huang X, Zhou L, Hao H. Polymorph transformation of solid drugs and inhibiting strategies. CrystEngComm. 2024;26(46):6510-6544.
59. Katiyar NK, Biswas K, Tiwary C. Cryomilling as environmentally friendly synthesis route to prepare nanomaterials. Int Mater Rev. 2021;66(7):493-532.
60. Guinet Y, Paccou L, Danède F, Willart JF, Derollez P, Hédoux A. Comparison of amorphous states prepared by melt-quenching and cryomilling polymorphs of carbamazepine. Int J Pharm. 2016;509(1-2):305-313.
61. Salem HF, Kharshoum RM. Nanoprecipitation technique for preparation of sterically stabilized risperidone nanosuspension: in vitro and in vivo study. Int J Pharm Pharm Sci. 2016;8(5):136-142.
62. Bøtker JP, Karmwar P, Strachan CJ, Cornett C, Tian F, Zujovic Z, Rantanen J, Rades T. Assessment of crystalline disorder in cryo-milled samples of indomethacin using atomic pair-wise distribution functions. Int J Pharm. 2011;417(1-2):112-119.
63. Murugesu B. Milling. In: Pharm Dosage Forms-Tab. CRC Press; 2008:191-210.
64. Prasertsri T. Preparation and stabilization of x-ray amorphous solid state structure of salbutamol sulfate adsorbed on mesoporous silica. Published online 2017.
65. El-Gendy N, Selvam P, Soni P, Berkland C. Development of budesonide nanocluster dry powder aerosols: processing. J Pharm Sci. 2012;101(9):3425-3433.
66. Chakraverty R, Das D, Debnath T. Organic Polymers and Their Role in Pharmaceutical and Chemical Industries. Org Polym Energy Environ Appl. Published online 2024:279-292.
67. Jin Y. Nanotechnology in pharmaceutical manufacturing. In: Pharm Manuf Handb Prod Process. John Wiley & Sons, Inc. Hoboken, New Jersey; 2008:1249-1288.
68. Mohl S. The development of a sustained and controlled release device for pharmaceutical proteins based on lipid implants. Ludwig Maximilian University of Munich. Doctoral degree. 2004.
69. Paaver U, Heinämäki J, Laidmäe I, Lust A, Kozlova J, Sillaste E, Kirsimäe K, Veski P, Kogermann K. Electrospun nanofibers as a potential controlled-release solid dispersion system for poorly water-soluble drugs. Int J Pharm. 2015;479(1):252-260.
70. Szentmihályi K, May Z, Bódis E, Tóth J, Trif L, Klébert S, Feczkó T, Károly Z. Morphology transformation of thermosensitive metronidazol by spray freeze-drying. J Therm Anal Calorim. 2022;147(21):11777-11786.
71. Kab CH, Nam PY, Yop RK. The effect of Milling Time and Speed on the Particle Size of Ibuprofen in the Cryogenic Ball Milling Process. Trans Korean Soc Mech Eng A. 2005;29(7):1022-1027.
72. Lee SM, Park HJ, Kim SS, Choi TH, Kim EZ, Na KH, Cho HK, Rhee KY. Particle size reduction of biomaterials using cryogenic milling process. In: Vol 475. Trans Tech Publ; 2005:2403-2406.
73. Rhee KY, Cho HK, Hong JS. An investigation on the application of cryogenic ball milling to ibuprofen particle and its characteristics. In: Materials Science Forum. Vol 505. Trans Tech Publ; 2006:355-360. Accessed March 7, 2025. https://www.scientific.net/MSF.505-507.355
74. Terebesi I, Bodmeier R. Optimised process and formulation conditions for extended release dry polymer powder-coated pellets. Eur J Pharm Biopharm. 2010;75(1):63-70.
75. Pas T, Bergonzi A, Michiels E, Rousseau F, Schymkowitz J, Koekoekx R, Clasen C, Vergauwen B, Van den Mooter G. Preparation of amorphous solid dispersions by cryomilling: chemical and physical concerns related to active pharmaceutical ingredients and carriers. Mol Pharm. 2020;17(3):1001-1013.
76. Megarry A, Booth J, Burley J. Amorphous trehalose dihydrate by cryogenic milling. Carbohydr Res. 2011;346(8):1061-1064.
77. Xu X, Siddiqui A, Srinivasan C, Mohammad A, Rahman Z, Korang-Yeboah M, Feng X, Khan M, Ashraf M. Evaluation of abuse-deterrent characteristics of tablets prepared via hot-

melt extrusion. AAPS PharmSciTech. 2019;20:1-11.

78. Ito T, Yamazoe E, Tahara K. Dry powder inhalers for proteins using cryo-milled electrospun polyvinyl alcohol nanofiber mats. Molecules. 2022;27(16):5158.
79. Thakral S, Govindarajan R, Suryanarayanan R. Processing-Induced Phase Transformations and Their Implications on Pharmaceutical Product Quality. Polymorph Pharm Ind: Solid Form Drug Dev. Published online 2018:329-380.
80. Han J, Wei Y, Lu Y, Wang R, Zhang J, Gao Y, Qian S. Co-amorphous systems for the delivery of poorly water-soluble drugs: Recent advances and an update. Expert Opin Drug Deliv. 2020;17(10):1411-1435.
81. Kapoor DU, Singh S, Sharma P, Prajapati BG. Amorphization of Low Soluble Drug with Amino Acids to Improve Its Therapeutic Efficacy: a State-of-Art-Review. AAPS PharmSciTech. 2023;24(8):253.
82. Laitinen R, Lobmann K, Grohganz H, Strachan C, Rades T. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability. Mol Pharm. 2014;11(7):2381-2389.

How to cite this article: Soni SJ and Patel AN. Pharmaceutical applications of cryogenic grinding: enhancing drug properties. Int J Appl Pharm Sci Res. 2024;9(1): 16-27. doi: https://doi.org/10.21477/ijapsr.9.1.02

Source of Support: Nil.

Conflict of Support: None declared.